<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00958815</url>
  </required_header>
  <id_info>
    <org_study_id>18FDG (completed)</org_study_id>
    <secondary_id>DK-020579</secondary_id>
    <nct_id>NCT00958815</nct_id>
  </id_info>
  <brief_title>Human Atherosclerotic Plaque Inflammation Imaged Using PDG-PET/CT</brief_title>
  <official_title>Human Atherosclerotic Plaque Inflammation Imaged Using PDG-PET/CT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      People with diabetes are at increased risk for atherosclerosis and have high CVD morbidity&#xD;
      and mortality rates. Tools for detecting and quantifying atherosclerotic pro/regression in&#xD;
      people with diabetes and other CVD risk factors lack sensitivity and specificity for&#xD;
      molecular level events that occur during the early stages of atherogenesis. Inflammatory&#xD;
      macrophage infiltration in the vessel endothelium is an early, molecular level proatherogenic&#xD;
      event. Activated macrophages consume glucose at a high rate. Novel in vivo radiotracer PET/CT&#xD;
      techniques have been developed to detect, image and quantify molecular level events like&#xD;
      macrophage inflammation and glucose utilization (18FDG) in human vessels. We propose to&#xD;
      develop and test this novel technique in the Center for Clinical Imaging Research (CCIR) at&#xD;
      WUMS. We propose that HIV-infected people with significant CVD risk profiles are a suitable,&#xD;
      unique human model for testing these novel imaging techniques. HIV-infected people taking&#xD;
      anti-HIV medications develop insulin resistance, T2DM, dyslipidemia, central adiposity, and&#xD;
      hypertension. HIV replicates in macrophages and represents a chronic proinflammatory&#xD;
      condition. Recent data indicate that HIV+ CVD risk have greater risk for atherosclerosis and&#xD;
      MI than HIV-negative people. To test feasibility, we hypothesize that: a.18FDG-PET/CT imaging&#xD;
      will detect more macrophage glucose uptake and inflammation in the carotid and aorta arteries&#xD;
      of HIV-infected people with CVD risk than in HIV-negative controls; b. radiotracer PET/CT&#xD;
      measures of proatherogenic processes will correlate with carotid intima media thickness; a&#xD;
      standard measure of carotid atherosclerotic burden. We propose to obtain pilot data that&#xD;
      shows feasibility for a novel analytical approach that will expand capabilities for&#xD;
      researchers interested in studying the links between diabetes, inflammation, and CVD in&#xD;
      humans.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Standard uptake values (SUV) for 18Fluoro-deoxyglucose in the carotid vessels and aorta of HIV-infected people with cardiovascular disease risk factors and compared to the same in HIV-seronegative people with no cardiovascular disease risk factors.</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Carotid intima media thickness measures will be compared to carotid 18FDG SUV.</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">14</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Atherosclerosis</condition>
  <condition>Cardiovascular Disease</condition>
  <condition>HIV/AIDS</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>HIV-seronegative with no CVD risk factors</arm_group_label>
    <description>Healthy, 35-60 yr old HIV-seronegative men and women with no CVD risk factors (normal fasting glucose tolerance, normal fasting lipid/lipoprotein levels, normotensive, waist circumference &lt;102cm (men) and &lt;88cm (women).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV+ with CVD risk factors</arm_group_label>
    <description>35-60 yr old HIV-infected men and women with insulin resistance, dyslipidemia, hypertension, and central adiposity.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be recruited through the AIDS Clinical Trials Unit (ACTU), Washington&#xD;
        University Infectious Diseases Clinics, primary care physicians in the community who refer&#xD;
        patients to these clinics and Volunteers for Health (VFH).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for HIV+ group:&#xD;
&#xD;
          -  confirmed HIV+ status&#xD;
&#xD;
          -  35-60 years old&#xD;
&#xD;
          -  stable ART for at least the past 4 mos&#xD;
&#xD;
          -  CD4 count &gt;200 cells/µL&#xD;
&#xD;
          -  HIV RNA &lt;40copies/mL&#xD;
&#xD;
          -  fasting glucose=100-126 mg/dL&#xD;
&#xD;
          -  2hr-oGTT glucose=140-200mg/dL&#xD;
&#xD;
          -  fasting triglycerides &gt;150mg/dL&#xD;
&#xD;
          -  HDL-cholesterol &lt;40mg/dL (men), &lt;50mg/dL (women)&#xD;
&#xD;
          -  resting blood pressure&gt;130/85mmHg&#xD;
&#xD;
          -  waist circumference &gt;102cm(men), &gt;88cm(women)&#xD;
&#xD;
          -  BMI 25-35 kg/m2&#xD;
&#xD;
        For HIV-negative control group:&#xD;
&#xD;
          -  Confirmed HIV negative status&#xD;
&#xD;
          -  35-60 years old&#xD;
&#xD;
          -  fasting glucose&lt;100mg/dL,&#xD;
&#xD;
          -  2hr-oGTT glucose&lt;140mg/dL&#xD;
&#xD;
          -  fasting triglycerides&lt;150mg/dL&#xD;
&#xD;
          -  HDL-cholesterol &gt;40mg/dL (men), &gt;50mg/dL(women)&#xD;
&#xD;
          -  normal BP (&lt;130/85mmHg)&#xD;
&#xD;
          -  no central adiposity (waist circ.&lt;102cm(men), &lt;88cm(women)&#xD;
&#xD;
          -  BMI (25-35 kg/m2)&#xD;
&#xD;
        Exclusion Criteria for both groups:&#xD;
&#xD;
          -  history of heart disease, MI, stroke, transient ischemic attack, kidney or liver&#xD;
             disease (active hepatitis B or C), dementia&#xD;
&#xD;
          -  statins, fibrates, TZDs, antihypertensives, low dose aspirin, or other&#xD;
             prescribed/over-the-counter agents with anti-inflammatory properties&#xD;
&#xD;
          -  cocaine and methamphetamine users&#xD;
&#xD;
          -  serum creatinine &gt;1.5 mg/dL&#xD;
&#xD;
          -  pregnant women&#xD;
&#xD;
          -  cognitive impairment that limits ability to provide voluntary informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin E Yarasheski, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St.Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.journal-inflammation.com/content/9/1/26/abstract</url>
    <description>Publication</description>
  </link>
  <results_reference>
    <citation>Yarasheski KE, Laciny E, Overton ET, Reeds DN, Harrod M, Baldwin S, Dávila-Román VG. 18FDG PET-CT imaging detects arterial inflammation and early atherosclerosis in HIV-infected adults with cardiovascular disease risk factors. J Inflamm (Lond). 2012 Jun 22;9(1):26. doi: 10.1186/1476-9255-9-26.</citation>
    <PMID>22726233</PMID>
  </results_reference>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>August 12, 2009</study_first_submitted>
  <study_first_submitted_qc>August 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2009</study_first_posted>
  <last_update_submitted>June 22, 2012</last_update_submitted>
  <last_update_submitted_qc>June 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Kevin Yarasheski</investigator_full_name>
    <investigator_title>Professor of Medicine, Cell Biology &amp; Physiology, Physical Therapy</investigator_title>
  </responsible_party>
  <keyword>vascular imaging</keyword>
  <keyword>diabetes</keyword>
  <keyword>rupture prone plaques</keyword>
  <keyword>HIV</keyword>
  <keyword>treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Plaque, Atherosclerotic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

